← All trials
NCT00238173
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2004
- Primary completion
- Feb 17, 2006
- Completion date
- Feb 17, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 2
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Oregon Health and Science UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Oregon Health and Science UniversityOverall official - principal investigator
- Oregon Health and Science UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.